By Jagjagran | 3 October 2026
The race for the next blockbuster weight-loss drug has a new contender. On 1 October 2026, results published in The New England Journal of Medicine showed that a new weekly injection, survodutide, helped people with obesity and type 2 diabetes lose up to 13.1% of their body weight — while also significantly improving their blood sugar.
Here's what the trial found.
THE TRIAL
The Phase 3 study, called SYNCHRONIZE-2 and run by Boehringer Ingelheim, tested survodutide in 755 adults with obesity and type 2 diabetes over 76 weeks.
Survodutide is a dual agonist — it acts on two hormone pathways (glucagon and GLP-1). By contrast, popular drugs like Ozempic and Wegovy act on GLP-1 alone.
THE RESULTS
→ Weight loss: up to 13.1% (company headline figure), versus 3.1% on placebo. In NEJM's main analysis counting all participants, the figure was 9.8% at the higher dose.
→ Blood sugar: HbA1c fell by up to 1.21 percentage points.
→ Remission: up to 29.5% of patients returned to normal blood sugar levels, versus 4% on placebo.
→ Waist size: reduced by up to 11.1 cm.
THE CATCH: SIDE EFFECTS
The main concern was tolerability. About 18% of people on survodutide stopped treatment due to gastrointestinal side effects — mainly nausea, vomiting, and diarrhoea — compared to just 1.2% on placebo.
Coordinating investigator Dr Sean Wharton offered perspective: "For people living with these conditions, sustained weight loss is often a biological struggle rather than a lack of willpower."
WHY IT MATTERS FOR INDIA
This is big news for a country facing a diabetes epidemic. India has around 89.8 million adults living with diabetes — the second-highest number in the world — projected to reach 156.7 million by 2050.
A drug that tackles both weight and blood sugar together could be valuable. However, there's an important caveat: survodutide is NOT yet approved anywhere in the world. It's still investigational, and regulatory approval is some way off.
THE BOTTOM LINE
Survodutide is the first Phase 3 proof that this new class of dual-hormone drug can improve both weight and blood sugar in people with diabetes. The weight loss is meaningful, but the side effects mean it may not be for everyone. The obesity-drug race just got more interesting.
FREQUENTLY ASKED QUESTIONS
Q: How much weight did survodutide help people lose?
A: Up to 13.1% of body weight in people with obesity and type 2 diabetes (9.8% in NEJM's main analysis).
Q: Is survodutide available to buy?
A: No. It is still investigational and not yet approved anywhere.
Q: How is it different from Ozempic?
A: Survodutide acts on two hormone pathways (glucagon and GLP-1); Ozempic acts on GLP-1 alone.
Sources: The New England Journal of Medicine (NEJM), Boehringer Ingelheim, Fierce Biotech, BioSpace, AJMC. This is not medical advice.
Comments
Post a Comment